Welcome to our dedicated page for Nevro news (Ticker: NVRO), a resource for investors and traders seeking the latest updates and insights on Nevro stock.
Nevro Corp (NYSE: NVRO), a pioneer in neuromodulation therapies for chronic pain management, provides this centralized hub for investors and healthcare professionals to access its latest developments. Track official press releases, clinical milestones, and business updates from the creator of the Senza spinal cord stimulation system.
This resource delivers timely updates on NVRO's FDA clearances, international expansions, and evidence-based innovations like its AI-enhanced HFX platform. Users will find disclosures covering product launches, financial results, and strategic partnerships that shape chronic pain treatment globally.
Key updates include advancements in 10 kHz therapy clinical applications, regulatory approvals across markets, and operational developments impacting patient access. Bookmark this page to stay informed about Nevro's progress in redefining neuromodulation standards through engineering and clinical excellence.
Nevro Corp. (NYSE: NVRO) reported its Q1 2023 financial results, showcasing a worldwide revenue of $96.3 million, up 10% from Q1 2022. Sales for the Painful Diabetic Neuropathy (PDN) indication surged 160% to approximately $15.6 million. U.S. revenue grew 12% to $82.3 million, with U.S. trial procedures up 9%.
However, the company faced a net loss of $36.3 million, compared to a $32.8 million loss in Q1 2022. The company initiated the launch of its AI-powered HFX iQ Spinal Cord Stimulation System and anticipates second quarter revenue guidance of $110 to $112 million. The full-year guidance maintains a revenue expectation of $445 to $455 million, representing 10% to 12% growth.
Nevro Corp. (NYSE: NVRO) announces the enrollment of the first patient in its Painful Diabetic Neuropathy (PDN) Sensory Study, marking a significant step as it is the first prospective randomized controlled trial aimed at assessing neurological function restoration in patients with intractable PDN. The study will include up to 236 patients and compares conventional treatment methods against 10 kHz Therapy combined with conventional management, facilitating optional crossover after 6 months.
The FDA has granted Breakthrough Device Designation, expediting the review for market application and expanding Nevro’s labeling. This designation aims to improve patient access to effective treatment options for debilitating conditions. The trial aims to confirm the benefits of the proprietary 10 kHz Therapy and may support better reimbursement strategies for PDN coverage.
Nevro Corp. (NYSE: NVRO), a leader in chronic pain treatment, has announced its participation in three significant investor conferences in May 2023. On May 10, CEO Kevin Thornal and CFO Rod MacLeod will present at the Bank of America 2023 Health Care Conference in Las Vegas at 5:00 pm PT. Following this, Rod MacLeod will present on May 16 at the JMP Securities Life Sciences Conference in New York at 11:00 am ET, and again on May 17 at the RBC Capital Markets Global Healthcare Conference at 11:30 am ET. Interested investors can access live webcasts and archived recordings from the events via Nevro's website. Nevro specializes in delivering innovative solutions for chronic pain, including the proprietary 10 kHz Therapy™ that benefits over 100,000 patients globally.
